{"database":"biostudies-arrayexpress","file_versions":[],"scores":null,"additional":{"omics_type":["Metabolomics","Unknown","Transcriptomics","Genomics","Proteomics"],"submitter":["Domenico Memoli"],"instrument_platform":["DNBSEQ-G400"],"study_type":["RNA-seq of coding RNA"],"organism":["Homo sapiens"],"species":["Homo sapiens"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/E-MTAB-11800"],"description":["Descrizione ProvvisoriaPurpose OC is characterized by a low response rate and high frequency of resistance development to currently available treatments, indicating to an urgent need for the identification of novel and more effective therapies. Several studies demonstrated DOT1L therapeutic potential in OC cells. However, DOT1L inhibitors efficacy and safety still require improvement that may be reached by combination targeting of this epigenetic modifier and its protein co-factors such as menin. Methods We applied siRNA-mediated gene knock-down and pharmacological inhibition coupled to cell proliferation assay on a panel of high grade serous OC cell lines in order to evaluate menin depletion and blockade effect on the proiferation of OC cells. We fully characterized processes,  transcript"],"repository":["biostudies-arrayexpress"],"sample_protocol":["Sample Collection - PEO1 (ECACC 10032308), PEO4 (ECACC 10032309), PEO14 (ECACC 10032311) were purchased from the American European Collection of Authenticated Cell Cultures (ECACC, Salisbury, UK), whereas ovarian cancer cell lines OVCAR-3 (HTB-161) and Caov-3 (HTB-75) were ordered from American Type Culture Collection (ATCC, Manassas, VA, USA)","Nucleic Acid Extraction - Cells were cultivated according to manufacturers’ instructions at 37°C and in the presence of 5%CO 2 . ATCC formulated RPMI 1640 medium (Euroclone, Milan, Italy), supplemented with 10%FBS (GE Healthcare, Chicago, IL) was used for maintenance of PEO1, PEO4, and PEO14 celllines. RPMI 1640 medium supplemented with 20% FBS and 0.01 mg/ml bovine insulin (Merck,Darmstadt, Germany) was used for cultivation of OVCAR-3 cell. Caov-3 cells were grown inDMEM (Euroclone) supplemented with 10% FBS. For all cell lines, 100 U/ml penicillin (Lonza,Basel, Swizzerland), 100 mg/mL streptomycin (Lonza), and 250 ng/mL Amphotericin-B (Merck)were added to the culture medium. Mycoplasma contamination of cells was routinely tested using amycoplasma PCR detection kit (ABM, Richmond, BC, Can","Sequencing - PEO1, PEO4 and PEO14 DNBs were sequenced in three independent runs on DNBSEQ-G400 MGI instrument.","Library Construction - For each sample, 1 µg of total RNA were used for rRNA depletion by using MGIEasy rRNA Depletion Kit (MGI). Then, the purified RNA was used as input for sequencing single-stranded circular DNA libraries preparation with MGIEasy RNA Directional Library Prep Set (MGI). Finally, according to the manufacturer’s’ instructions of DNBSEQ-G50RS High throughput Sequencing Kit (FCL PE100/FCS PE150) (MGI), single-stranded DNA libraries were used to make DNA nanoballs (DNBs)"],"figure_sub":["Organization","MINSEQE Score","Assays and Data","MAGE-TAB Files"],"pubmed_authors":["Domenico Memoli"],"additional_accession":[]},"is_claimable":false,"name":"Combinatorial Inhibition of Menin and the Histone Methyltransferase DOT1L as a Novel Therapeutic Strategy for Ovarian Cancer Treatment","description":"Descrizione ProvvisoriaPurpose OC is characterized by a low response rate and high frequency of resistance development to currently available treatments, indicating to an urgent need for the identification of novel and more effective therapies. Several studies demonstrated DOT1L therapeutic potential in OC cells. However, DOT1L inhibitors efficacy and safety still require improvement that may be reached by combination targeting of this epigenetic modifier and its protein co-factors such as menin. Methods We applied siRNA-mediated gene knock-down and pharmacological inhibition coupled to cell proliferation assay on a panel of high grade serous OC cell lines in order to evaluate menin depletion and blockade effect on the proiferation of OC cells. We fully characterized processes,  transcript","dates":{"release":"2026-08-01T00:00:00Z","modification":"2026-08-01T01:01:09.407Z","creation":"2026-07-17T16:24:22.069Z"},"accession":"E-MTAB-11800","cross_references":{"ENA":["ERP201407"],"EFO":["EFO_0002944","EFO_0004170","EFO_0005518","EFO_0003738","EFO_0004184"]}}